-
The Centers for Disease Control and Prevention is trying to overcome some stubborn myths and misperceptions about single-dose vials including the following, which the agency refuted with the current facts.
-
In what is getting to be a familiar, tragic refrain, the improper use of single-dose vials recently resulted in patients at pain clinics in Arizona and Delaware acquiring serious bacterial infections that were "completely preventable," the Centers for Disease Control and Prevention reports.
-
In light of recurrent outbreaks linked to misuse of single-dose medication vials, the Centers for Disease Control and Prevention is emphasizing that medications labeled as "single dose" or "single use" are to be used for only one patient.
-
Looking for a quality improvement (QI) project targeting catheter-associated urinary tract infections (CAUTIs)? Here's one that produced dramatic results, including a 68% decline in the CAUTI rate and a 20% reduction in the use of indwelling urinary catheters.
-
This study was a secondary analysis of data from an earlier randomized clinical trial comparing one antibiotic vs two (meropenem alone or meropenem plus ciprofloxacin) as early empiric therapy for ventilator-associated pneumonia (VAP).
-
-
In a recent discussion of a clinical case in the New England Journal of Medicine, the authors correctly indicate itraconazole is recommended for all but the most severe cases of disseminated histoplasmosis (when amphotericin B is used).
-
This ProMED-mail alert describes the case of a young Rhode Island resident who traveled to Cambodia and Viet Nam, where she was hospitalized with spinal cord compression in December 2011.
-
A total of 1745 infants from 17 sites in Brazil (70.1%), South Africa (27.4%), Argentina (1.6%) and the United States (0.8%) born to women with a peripartum diagnosis of HIV type I infection were randomized within 48 hours of birth to receive one of three six-week postpartum antiretroviral regimens.
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.